Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
AffiliationDepartment of Academic Surgery, National University of Ireland (NUI)/University, College Cork (UCC), Cork University Hospital, Cork, Ireland.
MetadataShow full item record
CitationBr J Cancer. 2006 Aug 7;95(3):247-52.
JournalBritish journal of cancer
AbstractThe toll-like receptor (TLR) system constitutes a pylogenetically ancient, evolutionary conserved, archetypal pattern recognition system, which underpins pathogen recognition by and activation of the immune system. Toll-like receptor agonists have long been used as immunoadjuvants in anti cancer immunotherapy. However, TLRs are increasingly implicated in human disease pathogenesis and an expanding body of both clinical and experimental evidence suggests that the neoplastic process may subvert TLR signalling pathways to advance cancer progression. Recent discoveries in the TLR system open a multitude of potential therapeutic avenues. Extrapolation of such TLR system manipulations to a clinical oncological setting demands care to prevent potentially deleterious activation of TLR-mediated survival pathways. Thus, the TLR system is a double-edge sword, which needs to be carefully wielded in the setting of neoplastic disease.
- TLR signaling by tumor and immune cells: a double-edged sword.
- Authors: Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H
- Issue date: 2008 Jan 7
- Toll-like receptors' two-edged sword: when immunity meets apoptosis.
- Authors: Salaun B, Romero P, Lebecque S
- Issue date: 2007 Dec
- Roles of toll-like receptors in cancer: a double-edged sword for defense and offense.
- Authors: Basith S, Manavalan B, Yoo TH, Kim SG, Choi S
- Issue date: 2012 Aug
- Prophylactic and therapeutic implications of toll-like receptor ligands.
- Authors: Hedayat M, Takeda K, Rezaei N
- Issue date: 2012 Mar
- Innate immunity and cancer therapy.
- Authors: Maruyama K, Selmani Z, Ishii H, Yamaguchi K
- Issue date: 2011 Mar